2026-06-01T01:04:19Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/243092026-02-03T11:34:46Zcom_10630_2254col_10630_37953

Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study) Valdés, Sergio Olveira-Fuster, Gabriel María Sánchez-Torralvo, Francisco José Vázquez-Pedreño, Luis Gonzalo-Marín, Montserrat Tapia Guerrero, María José Lima-Rubio, Fuensanta García-Fuentes, Eduardo García, Pilar Moreno-Ruiz, Francisco Javier Rodríguez-Cañete, Alberto Obesidad Intragastric injection of botulinum toxin A (BT-A) has been shown to be effective for weight loss up to six months after administration, according to previous studies. Our objective was to determine, in patients on bariatric surgery waiting lists, the effect of BT-A on weight loss in the pre- and postoperative period and to analyse if there are different responses based on Body Mass Index (BMI). Methods: We performed a follow-up analysis of the IntraTox study, which included 46 patients on bariatric surgery waiting lists in a single-centre, randomised, double-blind, placebo-controlled clinical trial. The treatment group received intragastric BT-A, whereas the control group received physiological saline solution. The one-time procedure was performed at the time of diagnostic endoscopy 7–8 months before surgery. Weight loss was evaluated at admission and after 4 and 12 weeks from the bariatric surgery. Our analysis was stratified by BMI at randomisation. Results: weight loss percentage on the day of surgery, with respect to the initial visit, was −4.5 ± 3.9% for the control group vs. −7.6 ± 4.2%, for the treatment group (p = 0.013). Weight loss percentage tended to remain greater in the treatment group one month after the intervention (−12.7 ± 4.7% vs. −15.2 ± 4.6%, p = 0.07) and become similar three months after (−21.6 ± 4.7% vs. −21.6 ± 4.6%). After stratifying by BMI, only patients with BMI over 50 kg/m2 allocated to the treatment group obtained a greater weight loss at the end of the trial, the day of surgery, and one month after, compared with the placebo group (−4.9 ± 4.9%, −10.8 ± 5.3% and −17.1 ± 3.8% vs. −0.1 ± 2.6%, −4.3 ± 3.2% and −12.8 ± 4.1%, respectively (p < 0.05). Conclusions: intragastric injection of BT-A is effective to achieve significant weight loss, especially in extreme obesity. Its use before bariatric surgery enhances perioperative weight loss. 2022-06-07T12:05:57Z 2022-06-07T12:05:57Z 2022-04-11 journal article Sánchez-Torralvo FJ, Vázquez-Pedreño L, Gonzalo-Marín M, Tapia MJ, Lima F, García-Fuentes E, García P, Moreno-Ruiz J, Rodríguez-Cañete A, Valdés S, Olveira G. Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study). Journal of Clinical Medicine. 2022; 11(8):2126. https://doi.org/10.3390/jcm11082126 https://hdl.handle.net/10630/24309 10.3390/jcm11082126 spa http://creativecommons.org/licenses/by/4.0/ open access Atribución 4.0 Internacional IOAP-MPDI